Sponsored Ad | Artotel Wonderlust: Waktu Indonesia Semarak - Leaderboard

China's RemeGen nets $100m led by Lilly Asia Ventures, Lake Bleu Capital

China's RemeGen nets $100m led by Lilly Asia Ventures, Lake Bleu Capital

RemeGen's buildings for the development of antibody and biological agents. Source: RemeGen

17 March, 2020

biopharmaceutical Lake Bleu Capital Lilly Asia Venture RemeGen

Printed by Unregistered user on Thu, 14 Aug 2025 05:58:51 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Chinese biopharma firm Akeso re-files for Hong Kong IPO

Venture Capital

Global biopharma firm HBM raises $75m from GIC, SK Holdings, others

Read more from Greater China

Earnings and Results

Tencent’s revenue grows 15% in Q2 as gaming, AI fuel growth

Climate Tech & ESG

Pricing reforms to slow China’s solar power capacity growth in H2